According to Fortune Business Insights, the global neuralgia treatment market was valued at USD 2.55 billion in 2025. The market is projected to grow from USD 2.72 billion in 2026 to USD 4.60 billion by 2034, exhibiting a CAGR of 6.79% during the forecast period from 2026 to 2034. Market growth is being driven by the increasing burden of chronic neuropathic pain, aging populations, greater diagnosis of nerve-related disorders, and growing adoption of drug-based and minimally invasive treatment options.
The global neuralgia treatment market includes drug-based therapies and surgical interventions used to manage different forms of nerve pain. Drug-based treatment includes anticonvulsants, antidepressants, topical lidocaine, capsaicin formulations, muscle relaxants, and selected analgesics.
For patients who do not respond adequately to medication, surgical and minimally invasive procedures provide additional treatment options. These include microvascular decompression, rhizotomy, stereotactic radiosurgery, radiofrequency ablation, nerve decompression, and neuromodulation.
The market is also being influenced by the increasing use of multidisciplinary treatment pathways. Neurologists, pain specialists, neurosurgeons, primary care physicians, and rehabilitation professionals are increasingly involved in managing complex neuralgia cases.
For detailed market insights: https://www.fortunebusinessinsights.com/neuralgia-treatment-market-118989
A major trend in the neuralgia treatment market is the growing emphasis on personalized pain management. Physicians are increasingly selecting therapies according to pain type, underlying condition, patient age, comorbidities, tolerability, and treatment response instead of relying on a single approach for every patient.
Another important trend is the increasing adoption of opioid-sparing treatment strategies. Healthcare providers are seeking safer long-term pain management options, supporting demand for anticonvulsants, antidepressants, topical therapies, nerve blocks, and other non-opioid interventions.
The market is also witnessing greater use of minimally invasive procedures. Microvascular decompression, rhizotomy, stereotactic radiosurgery, radiofrequency ablation, and neuromodulation are gaining importance for patients who do not achieve adequate relief through medication.
Digital health is another emerging trend. Pain-tracking applications, teleconsultations, electronic prescribing, and digital follow-up tools are helping providers monitor treatment response and support long-term patient management.
The increasing prevalence of chronic neuropathic pain is one of the primary factors driving market growth. Aging populations are more vulnerable to shingles-related complications, degenerative nerve compression, diabetes-related neuropathy, and other conditions associated with neuralgia.
As the number of patients seeking long-term pain relief increases, demand for pharmaceutical treatments, interventional procedures, and specialized neurosurgical care is also rising.
An aging population is contributing to a greater incidence of age-related nerve disorders. Older patients may also experience multiple chronic conditions, increasing the need for carefully managed pain therapies with appropriate tolerability and safety profiles.
Healthcare providers are consequently improving diagnostic pathways and expanding access to specialist care, supporting greater treatment uptake.
Increasing emphasis on safer pain management is encouraging pharmaceutical companies to develop differentiated non-opioid therapies. Manufacturers are focusing on improved tolerability, targeted mechanisms, topical delivery, extended-release formulations, and combination therapies.